Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Author(s):

Key Takeaways

AQP4-IgG+ NMOSD treatment has advanced with targeted therapies, notably anti-CD20 agents like rituximab, have led to increased relapse rates.
The clinical significance of these findings emphasizes personalized treatment strategies, offering improved disease management and patient care.
In practice, these data support the integration of novel therapies into standard protocols, aligning with observed improvements in patient outcomes.

Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have led to increased relapse rates.

Now Viewing

EP: 1.Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates

Video content above is prompted by the following:

Briefly review the current treatment landscape for aquaporin-4 IgG–seropositive (AQP4-IgG+) NMOSD and the role of anti-CD20 therapies, particularly rituximab.
Could you speak to the clinical significance of these findings and their implications for the neurology community?
How do these data compare to what you see in your clinical practice?